Literature DB >> 24402739

Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy.

F Bonilla-Abadía1, J F Betancurt, J C Pineda, J D Vélez, G J Tobón, C A Cañas.   

Abstract

New cases of Pneumocystis jirovecii pneumonia (PJP) have recently been reported in patients with systemic lupus erythematosus (SLE) after rituximab therapy. Several factors may contribute to susceptibility to P. jirovecii infection in this type of patients, including the immunological characteristics of the disease, the mechanisms of rituximab action, environmental factors, and the biological characteristics of the fungus. We report two patients with SLE who developed PJP after rituximab therapy.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24402739     DOI： 10.1007/s10067-013-2475-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  19 in total

Review 1.  Immunopathogenesis of Pneumocystis carinii pneumonia.

Authors:  Francis Gigliotti; Terry W Wright
Journal:  Expert Rev Mol Med       Date:  2005-11-14       Impact factor: 5.600

Review 2.  Rituximab-associated infections.

Authors:  Juan C Gea-Banacloche
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

3.  Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis.

Authors:  Boris Hugle; Melinda Solomon; Elizabeth Harvey; Adrian James; Anupma Wadhwa; Reshma Amin; Audrey Bell-Peter; Susanne Benseler
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06-25       Impact factor: 4.794

4.  B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection.

Authors:  Frances E Lund; Melissa Hollifield; Kevin Schuer; J Louise Lines; Troy D Randall; Beth A Garvy
Journal:  J Immunol       Date:  2006-05-15       Impact factor: 5.422

Review 5.  Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.

Authors:  Shouvik Dass; Edward M Vital; Paul Emery
Journal:  Expert Opin Pharmacother       Date:  2006-12       Impact factor: 3.889

6.  [Rituximab therapy for severe pediatric systemic lupus erythematosus].

Authors:  Gai-xiu Su; Feng-qi Wu; Fang Wang; Zhi-xuan Zhou; Xiao-lan Huang; Jie Lu
Journal:  Zhonghua Er Ke Za Zhi       Date:  2012-09

Review 7.  Aspects of immune dysfunction in end-stage renal disease.

Authors:  Sawako Kato; Michal Chmielewski; Hirokazu Honda; Roberto Pecoits-Filho; Seiichi Matsuo; Yukio Yuzawa; Anders Tranaeus; Peter Stenvinkel; Bengt Lindholm
Journal:  Clin J Am Soc Nephrol       Date:  2008-08-13       Impact factor: 8.237

8.  Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma.

Authors:  Hiroo Katsuya; Junji Suzumiya; Hidenori Sasaki; Kenji Ishitsuka; Takao Shibata; Yasushi Takamatsu; Kazuo Tamura
Journal:  Leuk Lymphoma       Date:  2009-11

9.  Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection.

Authors:  Fabio Bonilla-Abadía; Andrés F Echeverri; Jorge H Izquierdo; Felipe Cañas; Carlos A Cañas
Journal:  Case Rep Rheumatol       Date:  2012-12-16

10.  The interaction in vitro of Pneumocystis carinii with macrophages and L-cells.

Authors:  H Masur; T C Jones
Journal:  J Exp Med       Date:  1978-01-01       Impact factor: 14.307
View more
  6 in total

1.  β-Glucan-Activated Human B Lymphocytes Participate in Innate Immune Responses by Releasing Proinflammatory Cytokines and Stimulating Neutrophil Chemotaxis.

Authors:  Mohamed F Ali; Christopher B Driscoll; Paula R Walters; Andrew H Limper; Eva M Carmona
Journal:  J Immunol       Date:  2015-10-30       Impact factor: 5.422

2.  B cells modulate systemic responses to Pneumocystis murina lung infection and protect on-demand hematopoiesis via T cell-independent innate mechanisms when type I interferon signaling is absent.

Authors:  Teri R Hoyt; Erin Dobrinen; Irina Kochetkova; Nicole Meissner
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

Review 3.  Rituximab and lupus--a promising pair?

Authors:  Sara Linder Ekö; Ronald F van Vollenhoven
Journal:  Curr Rheumatol Rep       Date:  2014       Impact factor: 4.592

4.  Pneumocystis jirovecii Pneumonia in a Patient with Rheumatoid Arthritis Treated with Abatacept.

Authors:  Fabio E Ospina; Andrés Agualimpia; Fabio Bonilla-Abadía; Carlos A Cañas; Gabriel J Tobón
Journal:  Case Rep Rheumatol       Date:  2014-09-17

Review 5.  Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis.

Authors:  Xuqin Jiang; Xiaodong Mei; Di Feng; Xiaojing Wang
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

6.  Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients.

Authors:  Kai-Che Wei; Chenglen Sy; Shang-Yin Wu; Tzu-Jung Chuang; Wei-Chun Huang; Ping-Chin Lai
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.